ライフサイエンスコーパス: personalized medicine

1 for either diagnosis or to guide treatment ("personalized medicine").

2 iscusses their implications with respect to 'personalized medicine'.

3 sibility of genetic marker-guided treatment (personalized medicine).

4 l-based therapies an attractive strategy for personalized medicine.

5 n emerge as a powerful platform for enabling personalized medicine.

6 mismatched tissues and lack the advantage of personalized medicine.

7 ns, and so may be a viable option for future personalized medicine.

8 notypes to phenotypes for the development of personalized medicine.

9 cular systems biology, clinical research and personalized medicine.

10 tions for diagnostics and the development of personalized medicine.

11 selected features for various tasks such as personalized medicine.

12 ave myriad applications for regenerative and personalized medicine.

13 iologics can be tested and paves the way for personalized medicine.

14 plex diseases to make predictions useful for personalized medicine.

15 ch, and may provide critical information for personalized medicine.

16 turally important animals and crops, and for personalized medicine.

17 responsiveness are also important aspects of personalized medicine.

18 l for understanding phenotypic diversity and personalized medicine.

19 ncer biology, with potential applications to personalized medicine.

20 including antibiotic or cancer treatment in personalized medicine.

21 rovide cost-effective mobile health care and personalized medicine.

22 ome important clinical tools in the field of personalized medicine.

23 ce, and is important in applied breeding and personalized medicine.

24 ated clinical tests and the growing field of personalized medicine.

25 thy human proteome baseline is essential for personalized medicine.

26 ronmental monitoring, disease screening, and personalized medicine.

27 for the diagnosis of SNP-based diseases and personalized medicine.

28 l barriers to the wider potential success of personalized medicine.

29 esenting privileged tools for integrin-based personalized medicine.

30 eralized to other cancer types in the era of personalized medicine.

31 networks (from genomic sequences alone) for personalized medicine.

32 jor obstacle to effective cancer therapy and personalized medicine.

33 r new therapeutic targets and biomarkers for personalized medicine.

34 which is an unmet medical need in the era of personalized medicine.

35 ing of drug efficacy is highly desirable for personalized medicine.

36 tunities for early diagnosis of diseases and personalized medicine.

37 at the interface of chemistry, biology, and personalized medicine.

38 ing to the development of therapies based on personalized medicine.

39 ividuals is an important area in biology and personalized medicine.

40 a single system, may fulfill the promise of personalized medicine.

41 advantages in point-of-care diagnostics and personalized medicine.

42 ral health community's full participation in personalized medicine.

43 r obstacle to effective cancer treatment and personalized medicine.

44 tric disorders and may have implications for personalized medicine.

45 populations, with immediate implications for personalized medicine.

46 py to further the clinical implementation of personalized medicine.

47 imaging is paving the way for precision and personalized medicine.

48 ating clinical, imaging and genomic data for personalized medicine.

49 tanding of physiology and the development of personalized medicine.

50 g the range of therapeutic opportunities for personalized medicine.

51 pathophenotypes, towards more effective and personalized medicine.

52 s, and therapeutic intervention in an age of personalized medicine.

53 with other modified proteins of interest in personalized medicine.

54 platforms that are poised for application in personalized medicine.

55 of personality phenotype in the evolution of personalized medicine.

56 success of genetic mapping and the future of personalized medicine.

57 tional task in the development of precision, personalized medicine.

58 GPCRs holds promise for new therapeutics and personalized medicine.

59 technologies into their practice to advance personalized medicine.

60 be useful for research, clinical trials, and personalized medicine.

61 reatment of pain will move into the realm of personalized medicine.

62 fferences in drug response in the context of personalized medicine.

63 me fashion, potentially facilitating CER and personalized medicine.

64 be a tremendous asset to systems biology and personalized medicine.

65 might become useful tools in the practice of personalized medicine.

66 n electronic medical record is essential for personalized medicine.

67 s, thereby accelerating their translation to personalized medicine.

68 field of cardiovascular pharmacogenomics and personalized medicine.

69 more effective treatments and a step towards personalized medicine.

70 culating biomarkers as well as platforms for personalized medicine.

71 pment, and has potential application for the personalized medicine.

72 isk for disease is needed for preventive and personalized medicine.

73 ional Cancer Institute's program for CER and personalized medicine.

74 d holds great promise for the advancement of personalized medicine.

75 NPs) is an important topic in the pursuit of personalized medicine.

76 uced another poster child for the promise of personalized medicine.

77 rapies as we begin to move towards realizing personalized medicine.

78 ogically relevant genes, but less useful for personalized medicine.

79 rmophoresis a promising detection method for personalized medicine.

80 al diagnostics currently hinders advances in personalized medicine.

81 edisposition syndrome that is a paradigm for personalized medicine.

82 ally useful for a variety of applications in personalized medicine.

83 iation is expected to play a central role in personalized medicine.

84 y of the unique drug combinations needed for personalized medicine.

85 ior to human trials, within the framework of personalized medicine.

86 aterial for clinical risk stratification and personalized medicine.

87 llenges privacy and data deidentification in personalized medicine.

88 nses in patients, thereby paving the way for personalized medicine.

89 gy technology, dentistry, drug delivery, and personalized medicine.

90 ct in tissue engineering, cancer therapy and personalized medicine.

91 ht us to the doorstep of widespread usage of personalized medicine.

92 rug resistance mechanisms for advancement of personalized medicine.

93 e designed to facilitate cancer research and personalized medicine.

94 even more important from the perspective of personalized medicine.

95 adults because of the growing importance of personalized medicine.

96 es", holds promise for drastically improving personalized medicine.

97 and could be conducive to the development of personalized medicine.

98 applications within functional genomics and personalized medicine.

99 release has a pivotal role in the future of personalized medicine.

100 ic and will be a powerful tool in the era of personalized medicine.

101 (without pretreatment) in a single step for personalized medicine.

102 Biomarkers are rapidly gaining importance in personalized medicine.

103 om a one-size-fits-all approach to an era of personalized medicine.

104 , genes, and disease states, while advancing personalized medicine.

105 ponse, therefore paving the way towards more personalized medicine.

106 anisms of disease pathogenesis and promoting personalized medicine.

107 al for effective practical implementation of personalized medicine.

108 rating new hypotheses in cancer research and personalized medicine.

109 atient-specific cells for drug discovery and personalized medicine.

110 y and dysregulated elements is now informing personalized medicine.

111 ay be utilized in both genomics research and personalized medicine.

112 ity, which presents an important step toward personalized medicine.

113 olomics in the drug discovery process and in personalized medicine.

114 ed drug delivery), opening new dimensions in personalized medicine.

115 ease as we enter a new era of biomarkers and personalized medicine.

116 in biosensors as a result of the demand for personalized medicine.

117 ies in each child as a step toward achieving personalized medicine.

118 variation is a prerequisite for implementing personalized medicine.

119 typing, with transformative implications for personalized medicine.

120 plex genetic diseases and the development of personalized medicines.

121 is, and disease and might be used to develop personalized medicines.

122 Because we are now entering the era of personalized medicine, a systems biology approach mergin

123 Personalized medicine aims to individualize care based o

124 e the care of patients with AVD by promoting personalized medicine and early intervention.

125 ences will become increasingly important for personalized medicine and for fundamental biology.

126 uss the potential impact of such findings on personalized medicine and future avenues for screening,

127 n economy, or novel diagnostics impacting on personalized medicine and genetic disease.

128 er feedback therapy are the next frontier in personalized medicine and healthcare.

129 eir clinical translations for benefiting the personalized medicine and human health.

130 lowing statement: "Perhaps new directions in personalized medicine and improved health care access an

131 may help in the application of principles of personalized medicine and in decision making for targete

132 Changing demographics, the rise of personalized medicine and increased identification of bi

133 vel, which will be an important step towards personalized medicine and infectious disease management.

134 ed, for testing drugs or small molecules for personalized medicine and modeling cardiac disease in a

135 stem cell research holds vast potential for personalized medicine and novel therapies.

136 t microbial xenobiotic metabolism will guide personalized medicine and nutrition, inform toxicology r

137 In this era of personalized medicine and personalized prevention, we ne

138 ts reported in this work are significant for personalized medicine and point-of-care chemical treatme

139 elopment, help patient care planning through personalized medicine and support drug discovery program

140 The role of personalized medicine and target treatment in the clinic

141 roviding targeted therapies that will enable personalized medicine and the imaging tools to assess ou

142 individual's brain is a crucial step toward personalized medicine and understanding the neural basis

143 PCa detection is critical to personalized medicine and varies considerably under an M

144 samples and may present major challenges to personalized-medicine and biomarker development.

145 maceuticals across different patients (i.e., personalized medicine), and enabling cell-based therapie

146 , new collaboration networks in the field of personalized medicine, and future clinical implications

147 l decision-making, and early applications of personalized medicine appear to require strong clinical

148 e and raises the possibility of their use in personalized medicine applications.

149 rget interactions or phenotyping patients in personalized medicine applications.

150 Here we have designed a personalized medicine approach called gene expression an

151 er Genome Atlas database indicated that this personalized medicine approach could also be applied to

152 These findings support a personalized medicine approach for the treatment of nega

153 These findings strongly support a personalized medicine approach to alcoholism treatment t

154 To help improve the personalized medicine approach to psychiatric care, we e

155 r hormone replacement therapies as part of a personalized medicine approach to treating a variety of

156 the actual needs of each patient in a truly personalized medicine approach.

157 ck of evidence for biomarkers supporting the personalized medicine approach.

158 r patient outcomes compared with the current personalized medicine approach.

159 ormation arising from dynamic profiling in a personalized medicine approach.

160 at such biomarkers may offer evidence-based, personalized medicine approaches for optimally selecting

161 o have a large effect on systems biology and personalized medicine approaches that investigate the dy

162 lectric characterization are becoming viable personalized medicine approaches to treat a notoriously

163 erlies lymphomas and highlights the need for personalized medicine approaches to treating these patie

164 including non-druggable targets facilitates personalized medicine approaches with less adverse effec

165 vity provide a powerful framework to develop personalized medicine approaches, by helping to identify

166 hold special promise for the development of personalized medicine approaches.

167 t from a timely mechanistic insight enabling personalized medicine approaches.

168 ng of liver cancer biology and in developing personalized-medicine approaches for the disease.

169 Advances in personalized medicine are symbiotic with the development

170 Ideas about personalized medicine are underpinned in part by evoluti

171 ocesses for funding new medicines, including personalized medicines, are both robust and fit for purp

172 age fully in preparations for the arrival of personalized medicine as a means to provide quality, cus

173 search with the potential of applications in personalized medicine as well as in drug development.

174 enotype data is important for preventive and personalized medicine as well as plant and animal breedi

175 system has the potential for development of personalized medicines as the system would be capable of

176 ne, imaging, and computer science redefined "personalized medicine" as clinical care that takes advan

177 therapy and highlights the possible role for personalized medicine based on deiodinase polymorphisms.

178 tratified according to risk of IA, providing personalized medicine based on strategic evidence for th

179 matically increase over the next 10 years as personalized medicine becomes more of a reality for asth

180 valuation of Tdp2 status may be an important personalized medicine biomarker informing on individual

181 versity, enabling not just basic research in personalized medicine but also accurate diagnostics and

182 odels are becoming popular in the context of personalized medicine, but a new study shows that these

183 Molecular therapies are hallmarks of "personalized" medicine, but how tumors adapt to these ag

184 linical outcomes, has the potential to drive personalized medicine by enabling individualized risk st

185 fundamentally change clinical proteomics and personalized medicine by facilitating large-scale studie

186 abases are expected to play central roles in personalized medicine by providing targets for drug deve

187 With the age of personalized medicines demanding rapid bespoke diagnosis

188 o further scientific knowledge and to foster personalized medicine, despite a period of financial res

189 oth the epithelial and stromal compartments, personalized medicine efforts to integrate molecular inf

190 Clinicians already face "personalized" medicine every day while experiencing the

191 specific drugs, creating the possibility of personalized medicine for autism spectrum disorders.

192 icipated shift into a preventive paradigm of personalized medicine for breast cancer.

193 timately pave the way for the development of personalized medicine for cardiovascular diseases.

194 breakthrough-following genetics-toward more personalized medicine for genetic conditions, extending

195 rker tests are critical to implementation of personalized medicine for patients at risk for or affect

196 therapeutic benefit to usher in a new era of personalized medicine for patients with ABCB4-dependent

197 tool for developing anticancer therapies and personalized medicine for patients with cancer.

198 ons that may be useful in the development of personalized medicine for PC.

199 blood sampling could facilitate delivery of personalized medicine for SCLC.

200 are globally and opened up new prospects for personalized medicine for the fetus.

201 allenges that remain with the development of personalized medicine for treating a very complex spectr

202 ress is being made towards the final goal of personalized medicines for the treatment of complex dise

203 in technologies will continue to transition personalized medicine from the research to the clinical

204 The focus of personalized medicine has been primarily genomic medicin

205 would provide an autologous cell therapy for personalized medicine has been questioned.

206 Thus far, the focus of personalized medicine has been the prevention and treatm

207 Although personalized medicine has great promise, it has, so far,

208 Over the past decade, personalized medicine has received considerable attentio

209 The concept of personalized medicine has recently emerged as a promisin

210 and toolkits, such as microbial ecology and personalized medicine, have all embraced techniques that

211 Personalized medicines hold promise for many diseases.

212 Achieving personalized medicine, however, will require extensive r

213 ts with lung cancer is ushering in an era of personalized medicine; however, lack of actionable mutat

214 ed in four areas to realize the potential of personalized medicine: (i) processing large-scale robust

215 h is important to consider when implementing personalized medicine in asthmatic patients.

216 f targeted therapy has ushered in the era of personalized medicine in cancer therapy.

217 necessity of considering the age effects for personalized medicine in cancers.

218 development of biomarker-based approaches to personalized medicine in cardiovascular disease has been

219 Here, we describe examples of personalized medicine in cardiovascular disease, discuss

220 to biological treatment and can be used for personalized medicine in Crohn's disease and autoimmune

221 Here we discuss the promise of personalized medicine in developing more efficacious and

222 n genomic polymorphism data is important for personalized medicine in humans, plant and animal breedi

223 programs, and can aid in the development of personalized medicine in humans.

224 h EHRs to predict GDM, which will facilitate personalized medicine in maternal health management in t

225 ld great promise for quantifying response to personalized medicine in oncology.

226 nd that BTK-targeting SCOs have potential as personalized medicine in patients with XLA.

227 athways have drawn attention in the field of personalized medicine in recent years.

228 mice may lead to the implementation of truly personalized medicine in the clinic.

229 (pharmacogenetics) may usher in a new era of personalized medicine in the clinical management of AMD.

230 for studies of hematopoietic development and personalized medicine in the future.

231 we review the efforts of systems biology in personalized medicine in the past 2 years, and discuss i

232 ead toward the application of stratified and personalized medicine in the rhinitis field.

233 Personalized medicine includes identifying patients most

234 Perhaps new directions in personalized medicine including a systems biology approa

235 n recently because of their potential use in personalized medicine, including cancer-targeting treatm

236 otoxicity of tacrine, providing insights for personalized medicine initiatives.

237 Personalized medicine is expected to benefit from combin

238 Personalized medicine is likely to enter dentistry as pa

239 search; interdisciplinary work suggests that personalized medicine is on the horizon.

240 One important aspect of personalized medicine is patient-to-patient variation in

241 vide useful biomarkers, and the emergence of personalized medicine is poised to transform pharmaceuti

242 A major challenge in personalized medicine is the lack of a standard way to d

243 It may be that if the goal of personalized medicine is to be realized and biomarkers a

244 A widely acknowledged goal in personalized medicine is to radically reduce the costs o

245 "Personalized medicine" is a new concept in health care,

246 rstand the cancer resistance and move toward personalized medicine, it is essential to consider signa

247 As we move into an era of personalized medicine, it will become increasingly impor

248 Current personalized medicine matches therapy to a tumor molecul

249 markers and genomic risk profiles to develop personalized medicine might further improve asthma predi

250 he Human Genome Project and subsequently the personalized medicine movement.

251 drugs are currently under development, such personalized medicine offers a promising approach toward

252 A new personalized medicine paradigm is being considered to fa

253 d feasibility and patient enthusiasm for the personalized medicine paradigm, but have yet to demonstr

254 f genome-wide association studies (GWAS) and personalized medicine, predicting the impact of single n

255 Most physicians believe they practiced personalized medicine prior to the genomics era that fol

256 ogenomic data set to clinical application in personalized medicine programs is now the main challenge

257 Personalized medicine provides a strategic approach to t

258 delivery of aptamer-based drugs in smart and personalized medicine, providing a more efficient and sa

259 of TZD drugs, providing proof of concept for personalized medicine related to nuclear receptor genomi

260 The conventional approach to personalized medicine relies on molecular data analytics

261 Using the data from the Marshfield Personalized Medicine Research Project, a site in the el

262 The success of personalized medicine rests on understanding the genetic

263 Novel medical approaches and personalized medicine seek to use genetic information to

264 of xenobiotics, and suggest that attempts at personalized medicine should consider interindividual va

265 We will argue that randomized trials of personalized medicines should be routinely supplemented

266 netic architecture, a key step in developing personalized medicine strategies in the clinical managem

267 (and sometimes counterintuitive) nonstandard personalized medicine strategies may lead to superior pa

268 m cells (iPSCs) from human tissue for use in personalized medicine strategies or therapeutic testing

269 such models, such as for the development of personalized medicine strategies.

270 stematic study and evaluation of nonstandard personalized medicine strategies.

271 Cs therefore have great potential for use in personalized medicine strategies.

272 er tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results

273 ng many evidence-based concepts incorporates personalized medicine, systems-based practice, and conti

274 Current practice of personalized medicine tailors therapy to heterogeneity b

275 pproach constitutes a potential strategy for personalized medicine that enhances inference from stati

276 As a challenge for personalized medicine, the C-allele, which has an overal

277 on the formation and delivery of genomic and personalized medicine, the need for high-throughput and

278 In the era of personalized medicine, there is an urgent need for in vi

279 nologies are essential to the realization of personalized medicine through continuously monitoring an

280 The realization of personalized medicine through human induced pluripotent

281 ghput targeted proteomics, as is relevant to personalized medicine through robust protein biomarker v

282 d advanced PCa and underscore the benefit of personalized medicine to enhance treatment response.

283 new technology that offers the potential of personalized medicine to patients, yet little is known a

284 In this essay we link personalized medicine to the efforts of the early statis

285 ore their importance for topics ranging from personalized medicine to theories of the evolution of ho

286 int, which will enable clinicians to deliver personalized medicine to TMD patients and eventually pro

287 peptides are a promising next generation of personalized medicines to reinstate biological harmony.

288 provide a framework for developing tools for personalized medicine toward the precise prediction, pre

289 in cell biology with future applications in personalized medicine, tumor identification as well as t

290 In the era of personalized medicine, until a more biologically based u

291 Realizing personalized medicine, which promises to enable early di

292 ifts, market changes, and patient demand for personalized medicine will require physicians to embrace

293 Advances in cancer research and personalized medicine will require significant new bridg

294 Success in designing clinical trials for personalized medicine will require the selection of pati

295 Effective implementation of personalized medicine will require tools to distinguish

296 field are transforming our understanding of personalized medicine with an emphasis on cardiovascular

297 This novel machine-learning approach brings personalized medicine within reach, directly supporting

298 Thus, UPCs are suitable for personalized-medicine workflows where samples must be pr

299 However, in personalized-medicine workflows, samples may arrive seri

300 new urgency toward realizing the promise of personalized medicine; yet, many challenges stand in the